
Drugbox

<!Clinical data>

<! Legal status >

<! Pharmacokinetic data >

<! Identifiers >

<! Chemical and physical data >


Tulathromycin sold under the brand name Draxxin among others is a macrolide antibiotic used to treat bovine respiratory disease in cattle and swine respiratory disease in pigs

 Medical uses 
Tulathromycin is indicated for:

Cattle: Treatment and metaphylaxis of bovine respiratory disease (BRD) associated with Mannheimia haemolytica Pasteurella multocida Histophilus somni and Mycoplasma bovis sensitive to tulathromycin

Treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis sensitive to tulathromycin

Pigs: Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae Pasteurella multocida Mycoplasma hyopneumoniae Haemophilus parasuis and Bordetella bronchiseptica sensitive to tulathromycin

Sheep: Treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent Dichelobacter nodosus requiring systemic treatment

 Society and culture 
 Legal status 
Tulathromycin (brand name Draxxin) was approved for medical use in the European Union in November 2003

Tulathromycin (brand names Tulissin and Tulaven) was approved for medical use in the European Union in April 2020

On 16 July 2020 the Committee for Medicinal Products for Veterinary Use (CVMP) adopted positive opinions recommending the granting of marketing authorizations for the veterinary medicinal products Increxxa and Tulinovet solutions for injection for cattle pigs and sheep The applicant for Increxxa is Elanco GmbH

 Brand names 
It is marketed by Pfizer
It is marketed by Bimeda
It is also sold under the brand name Increxxa

References


 External links 
 






